Anti-PD-L1: Phase I data

Data from 160 evaluable patients with advanced solid tumors in the open-label, U.S. Phase I MDX1105-01 trial showed that IV BMS-936559 produced an objective response in 9 (17%) melanoma patients (n=52), 5 (10%) non-small cell lung cancer (NSCLC) patients (n=49), 1 (6%) ovarian cancer patient (n=17) and 2 (12%) renal cell carcinoma (RCC) patients (n=17). There were no objective responses in patients with colorectal (n=18) or pancreatic cancer (n=7). Additionally, 14 (27%) melanoma patients, 6 (12%) NSCLC patients, 3 (18%) ovarian cancer patients and 7 (41%) RCC patients achieved stable disease for >=24 weeks. Furthermore, 24-week PFS rates were 42% for melanoma patients, 31% for NSCLC patients, 22% for ovarian cancer patients and 53% for RCC patients. ...